Also Now in Arabic! متوفرة الآن بالعربيةView the Arabic Site

UncategorizedThe Booster Sinopharm Shot is Here

Abu Dhabi’s SEHA has announced that a third Sinopharm booster shot is available and is offered to anyone at least 6 months after they’ve had their second dose. Meanwhile, published results of Phase 3 trials of the Sinopharm vaccine show it is between 73 and 78 percent effective against Covid-19.
Anna PukasMay 30, 20215 min
عرض المقال بالعربية
Sinopharm vaccine

Abu Dhabi’s SEHA has announced that a third Sinopharm booster shot is available and is offered to anyone at least 6 months after they’ve had their second dose.

The third dose is also free of charge and doesn’t require a booking. It is currently available in over 100 vaccination centers across Abu Dhabi.

Meanwhile, published results of Phase 3 trials of the Sinopharm vaccine show it is between 73 and 78 percent effective against Covid-19.

The long-awaited study, which has been peer-reviewed, was published on May 26 in the Journal of the American Medical Association (JAMA). It combined the findings of trials conducted in the UAE, Bahrain, Egypt and Jordan involving more than 40,000 subject volunteers.
The Sinopharm vaccine, which uses a deactivated form of the Covid-19 virus to kickstart the body’s immune system, is manufactured by a state-run Chinese pharmaceutical company and was the first vaccine to be made available to UAE residents last December.
It had attracted some controversy because of the lack of peer-reviewed data from the trial and is still not recognized by some countries. However, the World Health Organization has authorized emergency use of the vaccine and now the endorsement by a prestigious US medical publication will go a long way toward alleviating any doubts about the vaccine’s efficacy.

The trials show that two vaccines developed by Sinopharm prevented Covid infections were 72.8 percent effective in preventing Covid infections with symptoms after a first jab and 78 percent effective after two jabs.

In the trial, the volunteers were split into three groups. Two of the groups received two doses of one of the Sinopharm vaccines while the third group were given a placebo. Two weeks after receiving the second jab, infections developed in 26 people from one vaccine group and in 21 people from the other. In the placebo group, 95 became infected.

However, none of the volunteers who received the vaccine became seriously ill.

The trial results were submitted to the JAMA on March 17 and accepted for publication on May 12.

This story was updated May 30, 2021 with updates on the Sinopharm booster shot.

Anna Pukas

Anna Pukas has reported from all over the world as a foreign correspondent for British media. She is now an editor based in Abu Dhabi.